Literature DB >> 30719605

Association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population: a case control study.

Richa Bhatnager1, Alka Senwal1, Smiti Nanda2, Amita S Dang3.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of reproductive-aged women. PCOS reflects a number of possible etiologies but its pathophysiology is still unclear. The principal abnormality of the syndrome is hyperandrogenism (70-80%). The access of androgens to target tissues is regulated by sex hormone-binding globulin (SHBG), a transport protein secreted by liver i.e. specific for androgens. Present study was done to find the association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population. Present study was a case control study. 400 subjects were enrolled for the study and serum SHBG levels and D327N polymorphism were measured. The D327N polymorphism (wild-type and variant allele) was detected using PCR-RFLP method (restriction enzyme Bbs-I). PCOS group was found to have significantly lower SHBG levels than healthy controls. There was no significant difference in genotype distribution between PCOS and controls (χ2 = 1.0335, p = 0.59). Significant difference in SHBG levels of PCOS and control group highlights the potential of SHBG as a biomarker for PCOS. However, no significant difference in genotype distribution between PCOS and controls provided an insight that rs6259 polymorphism is not associated with the risk of PCOS and SHBG levels.

Entities:  

Keywords:  Diagnostic marker; PCOS; Polymorphism; SHBG; Susceptibility marker

Mesh:

Substances:

Year:  2019        PMID: 30719605     DOI: 10.1007/s11033-019-04665-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  Association of the (TAAAA)n repeat and Asp327Asn polymorphisms in the sex hormone-binding globulin (SHBG) gene with idiopathic male infertility and relation to serum SHBG concentrations.

Authors:  Mohammad Reza Safarinejad; Nayyer Shafiei; Shiva Safarinejad
Journal:  J Steroid Biochem Mol Biol       Date:  2010-10-23       Impact factor: 4.292

2.  Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome.

Authors:  Bela Bendlová; Jana Zavadilová; Markéta Vanková; Daniela Vejrazková; Petra Lukásová; Josef Vcelák; Martin Hill; David Cibula; Karel Vondra; Luboslav Stárka; Jana Vrbíková
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-26       Impact factor: 4.292

3.  The (TAAAA)n polymorphism of the SHBG gene in men with the metabolic syndrome.

Authors:  N Xita; H J Milionis; A Galidi; L Lazaros; K Katsoulis; M S Elisaf; I Georgiou; A Tsatsoulis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-08-05       Impact factor: 2.949

Review 4.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

Review 5.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

6.  The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women.

Authors:  Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden
Journal:  J Clin Endocrinol Metab       Date:  2009-09-29       Impact factor: 5.958

7.  Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women.

Authors:  Patrice Cousin; Laurence Calemard-Michel; Hervé Lejeune; Gérald Raverot; Nadia Yessaad; Agnès Emptoz-Bonneton; Yves Morel; Michel Pugeat
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

Review 8.  Plasma steroid-binding proteins.

Authors:  W Rosner
Journal:  Endocrinol Metab Clin North Am       Date:  1991-12       Impact factor: 4.741

9.  Asp327Asn polymorphism of sex hormone-binding globulin gene is associated with systemic lupus erythematosus incidence.

Authors:  Piotr Piotrowski; Robert Gasik; Margarita Lianeri; Dorota Cieślak; Mariusz Wudarski; Paweł Hrycaj; Jan K Łacki; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2009-08-01       Impact factor: 2.316

10.  The Asp(327)Asn polymorphism in the sex hormone-binding globulin gene modifies the association of soy food and tea intake with endometrial cancer risk.

Authors:  Wang Hong Xu; Wei Zheng; Qiuyin Cai; Jia-Rong Cheng; Hui Cai; Yong-Bing Xiang; Xiao Ou Shu
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

View more
  2 in total

1.  The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Chuan Xing; Han Zhao; Jiaqi Zhang; Bing He
Journal:  Front Physiol       Date:  2022-05-09       Impact factor: 4.755

2.  Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium.

Authors:  Jose M Sánchez-Maldonado; Rafael Cáliz; Luz Canet; Rob Ter Horst; Olivier Bakker; Alfons A den Broeder; Manuel Martínez-Bueno; Helena Canhão; Ana Rodríguez-Ramos; Carmen B Lupiañez; María José Soto-Pino; Antonio García; Eva Pérez-Pampin; Alfonso González-Utrilla; Alejandro Escudero; Juana Segura-Catena; Romana T Netea-Maier; Miguel Ángel Ferrer; Eduardo Collantes-Estevez; Miguel Ángel López Nevot; Yang Li; Manuel Jurado; João E Fonseca; Mihai G Netea; Marieke J H Coenen; Juan Sainz
Journal:  Sci Rep       Date:  2019-10-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.